{
  "created_at": "Fri Oct 15 17:5:18 +0000 2021",
  "id_str": "1449050974161604615",
  "full_text": "Breaking: The FDA has delayed a decision on clearing Moderna's Covid-19 vaccine for 12-to-17-year-olds while it looks into the risk of the rare heart condition myocarditis, people familiar with the matter say https://t.co/fIs0sypYzv",
  "display_text_range": [
    0,
    232
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/fIs0sypYzv",
        "expanded_url": "https://on.wsj.com/3mXRx0P",
        "display_url": "on.wsj.com/3mXRx0P",
        "indices": [
          209,
          232
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 59,
  "favorite_count": 98,
  "possibly_sensitive": false,
  "original_created_at": "Fri Oct 15 16:34:08 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "Breaking: FDAは、稀な心臓疾患である心筋炎のリスクを調査する間、Moderna社のCovid-19ワクチンを12歳から17歳の子供に承認するかどうかの決定を遅らせている、と関係者が語った。https://t.co/fIs0sypYzv"
    },
    {
      "locale": "zh",
      "full_text": "突破。熟悉此事的人士说，美国食品和药物管理局已推迟决定批准Moderna公司为12至17岁儿童接种Covid-19疫苗，同时研究罕见的心脏病心肌炎的风险，https://t.co/fIs0sypYzv。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "突破。熟悉此事的人士說，美國食品和藥物管理局已推遲決定批准Moderna公司爲12至17歲兒童接種Covid-19疫苗，同時研究罕見的心臟病心肌炎的風險，https://t.co/fIs0sypYzv。"
    }
  ]
}